margin continu derisk
haemonet continu deliv signific profit
continu see larg custom contract focu
remain comfort consensu number regardless
anoth profitability-driven quarter report revenu
organ line model impli bp
momentum deceler plasma revenu organ
gener line model even collect volum recov modestli
expect grow hsd vs outlook
discuss hospit vs mse miss estim due
variat capit equip cycl off-set blood center
vs mse favor order time japan compani
continu drive materi margin upsid margin bp y/i
bp estim driven product benefit favor mix
disciplin spend guidanc rais vs prior
third consecut quarter beat/rais averag margin beat bp
year impli bp declin margin see
conserv given close provid outlook ep
beat estim mainli driven gross oper margin upsid
vs mse bottom line guidanc also rais third consecut
quarter y/i
plasma commentari impli slowdown plasma organ growth guidanc
reiter manag point lower end rang
would impli organ growth point momentum
deceler modest chang vs model given collect volum
forecast grow hsd vs dd expect previous
referenc overli surpris absenc nexsi
price tailwind experienc last month estim point
natur na dispos growth approach collect volum
nexsi valu proposit continu seen manag suggest
nexsi collect grew non-nexsi custom turn
rate continu improv model organ growth point
momentum deceler remain comfort see underli
plasma growth rang remain comfort mid-point
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
note increment /- point plasma growth drive bp corpor
contract guidanc prior quarter new inform
receiv regard potenti time grifols/csl contract said
commentari increment posit regard nexlynk penetr
manag disclos na custom migrat
migrat nexlynk cover sean laaman australia
nexlynk see unclear whether impli grifol start
adopt nexlynk inventori grew q/q vs prior two quarter
appear level convers suggest manag
built inventori comfort level continu modestli grow
inventori drive suppli chain flexibl see
telltal sign lead indic immin contract consist
dilig respect guidanc manag includ
financi benefit contract unless hand time guidanc
may see prudent said light signific profit
inflect futur benefit cost-sav program see
consensu estim reach without contract see re-
evalu top bottom line assumpt approach
guidanc may
track versu long-rang plan lrp adjust
restat see remain well track deliv plasma
lrp target compound-annual-growth-rate without contract
model current impli plasma contract even
adjust estim contract valu still arriv within
rang base current model impli organ growth blood
center also see compani achiev top end lrp target
hospit remain segment compani like
fall short growth next year would still impli short low end
lrp rang within hospit teg perform improv grew
quarter manag reiter intent deliv doubl ebit
effect impli done without
presenc contract see new inform
extens discuss dynam note street model
alreadi consensu model ebit
contract may drive near-term sentiment profit continu regardless
haemonet share under-perform point
investor began question viabil larg custom contract
number mention continu expect key focu near-term
regardless analysi impli profit inflect continu
without contract see see compani becom activ
capit deploy buyback potenti long-term
explor strateg option blood busi remain overweight
share price target base
ebitda estim premium smid cap peer given superior
organ growth profil materi greater oper leverag
price target reflect ebitda five-turn
premium smid cap peer given superior organ growth profil
upsid nexsi price complex reduct initi drop
balanc sheet option drive ebit achiev
per liter increment plasma price nexsi greater cost
save drop balanc sheet option third parti financ
capit deploy drive materi upsid ebit
nexsi cost restructur program drive ebit
haemonet abl achiev favor increment plasma price
nexsi save help compani exceed lrp ebit object
nexsi unabl gain materi price benefit nexsi unabl creat
materi valu custom and/or unabl obtain
competit price plasma growth remain line market growth rate
minim cost save drop
stori tie long-
rang plan lrp doubl oper incom
quadrupl turnaround
primarili lever nexsi compani
valu creation materi yield
opportun appreci see
posit backdrop nexsi drive
valu per liter plasma
custom expect share
profit increment per
liter price indic nexsi alon
drive lrp object
drive materi inflect
nexsi drive increment valu
per liter plasma custom
haemonet expect particip
oper excel program
drive bp margin
capit deploy via buyback
announc larg custom nexsi
capit deploy via buyback
progress cost restructur program
risk achiev price
larg custom declin convert
save program fail materi
million except ep
sale
sale
sale
sale
sale
sale
good sold
equival
accum comprehens incom
loss asset dispos
chang work capit
net provid oper activ
capit intang asset
sale properti invest
net use invest activ
chang equiti
net financ activ
net chang
equival bop
equival eop
